Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 32 results for alzheimer's disease

  1. Dementia: assessment, management and support for people living with dementia and their carers (NG97)

    This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

  2. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

  3. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: 17 July 2024

  4. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 11 September 2024

  5. Physical activity: brief advice for adults in primary care (PH44)

    This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.

  6. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

  7. Gantenerumab for treating early Alzheimer's disease TS ID 10668

    Awaiting development [GID-TA11072] Expected publication date: TBC

  8. Hydromethylthionine mesylate for treating Alzheimer's disease TS ID 11890

    Awaiting development [GID-TA11379] Expected publication date: TBC

  9. Prevent or delay the onset of dementia

    NICE's impact on preventing or delaying the onset of dementia

  10. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  11. Research is needed on the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).

    the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between...

  12. Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer's disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.

    data on the effects of treating people with Alzheimer's disease on both short-term and long-term outcomes, disease...

  13. Our projects and partners

    NICE research projects and partners.

  14. NICEimpact dementia

    How NICE recommendations are being used to improve outcomes in priority areas of dementia care

  15. Referral, diagnosis and care planning

    NICE's impact on dementia referral, diagnosis and care planning